Michelle A Hsu

7PUBLICATIONS
34CO-AUTHORS
Molecular targetsTumour immunologyInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 06, 2026
Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

|Jul 07, 2026
Loss of the kinases TBK1 and IKKε sensitizes target cancer cells to T cell killing through an IFN-γ-mediated inflammatory death program.

|May 23, 2026
PD-1 regulates latent effector differentiation of thymic cytotoxic CD8+ T cells.

|Oct 28, 2025
Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion.

Michelle A Hsu, Xin Liu, Whitney Barham

|Aug 16, 2024
TBK1 and IKKε protect target cells from IFNγ-mediated T cell killing via an inflammatory apoptotic mechanism.

Nicholas D Sun, Allison R Carr, Erica N Krogman

|Nov 15, 2023
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation.

Joanina K Gicobi, Zhiming Mao, Grace DeFranco

Pageof 2

Frequent Collaborators

6 joint publications

Haidong Dong

4 joint publications

Fabrice Lucien-Matteoni

3 joint publications

Adrian T Ting

2 joint publications

Joanina K Gicobi